Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
In research models, this peptide binds to specific receptors in the pituitary gland (pituitary gland), leading to an increased release of growth hormone
With an extended half-life and enhanced bioavailability, IGF-1 LR3 is ideal for exploring cell growth , recovery pathways , and anabolic signaling in controlled research environments
Collagen changes become more apparent
This is why interest in supporting glutathione levels has grown so quickly
Several studies have shown that PEA is effective in reducing symptoms of IBS, such as abdominal pain and bloating